Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Prior treatment

• Patients who have been treated with pemetrexed if the last dose of pemetrexed is \< 30 days to the date of surgery.
• Patients that have been treated with prior Mantle field radiation.
• Subjects who have received more than 2 doses of neo-adjuvant chemotherapy

Other illness

• Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer
• Patients who have a history of HIV disease.
• Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.
• Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax.

Lab values

• Patients who have a white count less than 2,500 per cubic mm or platelets less than 100,000/cubic mm.
• Serum creatinine equal or greater than 2.5 mg/deciliter.
• Patients who have severe liver disease including cirrhosis, Grade III-IV elevations in liver function studies, or bilirubin in excess of 1.5 mg/deciliter.

Other

• Pregnant or lactating patients.

• Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumor.
• Patients must have disease limited to the hemithorax.
• Patients who have received prior surgery, gene therapy, or combination chemotherapy will be permitted if it has been at least 30 days since the last treatment.
• Subjects treated with pemetrexed previously will be eligible only if 30 days have elapsed between the last dose of pemetrexed and the date of surgery.
• ECOG performance status of 0-1.
• Medical suitability for resection, including documented medical and cardiac clearance.
• 18 years of age or older.
• Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks. Patients unwilling or unable due to cognitive impairment to sign informed consent are excluded from the study.